A shorter MPFI designed specifically for patients with chronic pain proved generally valid and reliable on a group level, according to a recent study.

The Alzheimer's Association revised the diagnostic criteria for Alzheimer disease (AD) and ADRD for clinicians in primary and specialty care.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).